Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRGN-3006

Cell therapy (CAR-T) · Kills target cells, directed at CD33 · developed by Precigen

Phase 1 Most advanced trial
PGEN Developer
1 Registered trials

What is PRGN-3006?

PRGN-3006 is an autologous T-lymphocyte preparation genetically modified to express an anti-CD33 chimeric antigen receptor, membrane-bound IL-15, and a safety switch. The CAR-T cells bind CD33-expressing tumor cells to induce selective toxicity, and are studied in acute myeloid leukemia and myelodysplastic syndromes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD33 (antigen)
Mechanism
Kills target cells, directed at CD33
Pathways
IL-15 signaling, T-cell memory maintenance
Therapy area
Oncology
Developer
Precigen, Inc (PGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03927261 Phase 1 Acute Myeloid Leukemia Active not recruiting PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Other drugs acting on CD33

More from Precigen

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.

Follow PGEN, the company behind PRGN-3006

See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.